Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Cell Division drug effects MeSH
- Doxorubicin chemistry pharmacokinetics pharmacology MeSH
- Colorectal Neoplasms drug therapy MeSH
- Humans MeSH
- Lymphoma, T-Cell drug therapy MeSH
- Methacrylates chemistry pharmacology MeSH
- Molecular Structure MeSH
- Antibodies, Monoclonal chemistry metabolism MeSH
- Mice, Inbred BALB C MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prodrugs chemistry pharmacology MeSH
- Antibiotics, Antineoplastic chemistry pharmacokinetics pharmacology MeSH
- In Vitro Techniques MeSH
- Tissue Distribution MeSH
- Neoplasm Transplantation MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Doxorubicin MeSH
- hydroxypropyl methacrylate MeSH Browser
- Methacrylates MeSH
- Antibodies, Monoclonal MeSH
- Prodrugs MeSH
- Antibiotics, Antineoplastic MeSH
PURPOSE: Two different monoclonal antibody-targeted HPMA copolymer-doxorubicin conjugates, classic and starlike, were synthesized to be used for site-specific cancer therapy. The anti-mouse Thy-1.2 (IgG3) and two anti-human CD71/A (IgG1) and CD71/B (IgG2a) monoclonal antibodies were used as targeting structures. METHODS: Their binding and cytotoxic activity in vitro, body distribution, and anticancer activity in vivo were evaluated. RESULTS: The results of flow cytometric analysis showed comparable binding of classic and starlike conjugates to the target cells. The in vitro cytotoxic effect was 10-fold higher if cancer cells were exposed to the starlike conjugate compared to the classic one. Biodistribution studies showed that the starlike conjugate remained in a relatively high concentration in blood, whereas the classic conjugate was found in a 6.5-times lower amount. In contrast to the low antitumor activity of free doxorubicin and nontargeted HPMA copolymer-doxorubicin conjugate, both anti-Thy-1.2 targeted conjugates (classic and starlike) cured all mice bearing T-cell lymphoma EL4. On the other hand, starlike conjugates containing anti-CD71/A or anti-CD71/B monoclonals as targeting structures were more effective against human colorectal cancer SW 620 than the classic one. CONCLUSIONS: We have shown that the starlike conjugates are more effective systems for targeted drug delivery and cancer treatment than classic conjugates.
See more in PubMed
Bioconjug Chem. 2002 Mar-Apr;13(2):206-15 PubMed
Adv Drug Deliv Rev. 1998 Feb 2;29(3):273-289 PubMed
Ann N Y Acad Sci. 1997 Dec 31;831:47-56 PubMed
Sel Cancer Ther. 1991 Summer;7(2):59-73 PubMed
Clin Immunol Immunopathol. 1988 Jan;46(1):100-14 PubMed
Nat Biotechnol. 1999 Nov;17 (11):1101-4 PubMed
J Control Release. 2002 Jan 17;78(1-3):97-114 PubMed
J Immunol. 1988 Dec 15;141(12):4410-7 PubMed
Eur J Cancer. 1977 Sep;13(9):925-35 PubMed
J Drug Target. 1996;3(5):357-73 PubMed
Adv Exp Med Biol. 2003;519:125-43 PubMed
J Drug Target. 2002 Feb;10 (1):23-30 PubMed
J Control Release. 2000 Feb 14;64(1-3):63-79 PubMed
J Control Release. 2000 Feb 14;64(1-3):241-61 PubMed
